Recent News

• 01.27.2026 - Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
• 01.12.2026 - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
• 01.06.2026 - Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
• 12.19.2025 - Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
• 10.29.2025 - Aclaris Therapeutics to Participate in Three November Healthcare Conferences
• 10.14.2025 - 2025 R&D Day

Recent Filings

• 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 01.09.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - EX-99.1 EX-99.1
• 01.06.2026 - 8-K Current report
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities